reviewNew England Journal of MedicineJul 4, 2007Closed access

Trastuzumab — Mechanism of Action and Use in Clinical Practice

CAClifford A. Hudis

Memorial Sloan Kettering Cancer Center

PubMed
Indexed incrossrefpubmed

Abstract

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.

Citation impact

2,573
total citations
FWCI
54.55
Percentile
100%
References
92
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Trastuzumab
  • Medicine
  • Mechanism of action
  • Monoclonal antibody
  • Breast cancer
  • Monoclonal
  • Mechanism (biology)
  • Food and drug administration
No related works found for this paper.